Get access

The Epstein–Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis


Correspondence to:Caroline Alfieri
Sainte-Justine Hospital Research Centre
3175 Côte Ste-Catherine Road
Montreal, Quebec
H3T 1C5 Canada
Tel: +514 345 4931,
ext 6135
Fax: +514 345 4801


Abstract: Transplant patients are at particular risk for developing post-transplant lymphoproliferative disease (PTLD) following administration of immunosuppressive therapy. In many cases the PTLD lesions express Epstein–Barr virus (EBV) latent and lytic genes as well as elevated levels of host cytokines. An outline of the potential contributions of EBV, host cytokines and T cells, and the immunosuppressives cyclosporine A, tacrolimus, and anti-CD3 antibody in the mechanism and pathogenesis of this disease is presented and discussed.

Get access to the full text of this article